DOSAGE SCHEME OF TUMOR NECROSIS FACTOR-THYMOSINE ALPHA 1 RECOMBINANT (REFNOT) PRODUCT MANUFACTURED BY “REFNOT-PHARM” LLC, RUSSIA
Treatment regimens for breast cancer patients combined with chemotherapy:
1st day: 30 minutes prior to chemotherapy TNF-T (Refnot) in the dosage of 200 000 units at once s/c + chemotherapy + standard antiemetic therapy.
Recommendations: The drug is injected subcutaneously to the outer surface of upper arm or femur, the injection points are interchanged. If the hematologic toxicity of the treatment is presented, the dosage of chemotherapeutic agents is reduced for all following cycles according to the appointed regimes. To increase antitumor and immunomodulating effects of the therapy additional injection of interferon gamma (Ingaron produced by “Research and production Enterprise “Pharmaclone” LLC, Russia) is recommended.
The scheme of interferon gamma + TNF-T + chemotherapy:
the day prior to chemotherapy interferon gamma (Ingaron) in the dosage of 500000 IU once intramuscularly or subcutaneously. 1st day: 30 minutes prior to chemotherapy TNF-T (Refnot) in the dosage of 200000 units at once subcutaneously + chemotherapy + standard antiemetic therapy. 2nd, 4th, 6th, 8th days: interferon gamma (Ingaron) in the dosage of 500000 IU at once intramuscularly or subcutaneously one time a day. 3rd, 5th, 7th, 9th days: TNF-T (Refnot) in the dosage of 200000 units at once subcutaneously one time a day. Course dose of TNF-T (Refnot) is 1 mln units (2 packages); course dose of interferon gamma (Ingaron) is 2.5 mln IU (1 package). (The efficiency is proved during clinical trials conducted by Federal State Institution Research and Development Establishment of Oncology named after N.N. Petrov under the supervision of the institute director, an associate member of the Russian Academy of Sciences, professor, Doctor of Medical Sciences V.F. Semiglazov).
Recommendations: If the drug is injected subcutaneously, the injection points are interchanged. . If the hematologic toxicity of the treatment is presented, the dosage of chemotherapeutic agents is reduced for all following cycles according to the appointed regimes.
The schemes of treating cancer patients with REFNOT product as an immunomodulator
Scheme with chemotherapy:
TNF-T (Refnot) in the dosage of 100000-400000 units at once subcutaneously 5 days a week, then a 2-day pause during 2-4 weeks prior to chemotherapy course. (The efficiency is proved during clinical trials conducted in the department of combined method treatment State Establishment “Russian Cancer Research Center named after Nikolai Blokhin” of the Russian Academy of Medical Sciences under the supervision of deputy director of science department, an associate member of the Russian Academy of Sciences, professor, Doctor of Medical Sciences M.R. Lichinitser).
Recommendations: The drug is injected subcutaneously to the outer surphace of upper arm or femur, the injection points are interchanged. In case of thrombocytopenia less than 80х103/µL, the injection of TNF-T (Refnot) should be stopped until the number of thrombocytes increases to the minimum of 100х103/µL. The treatment should be continued until the progress is reached or the limiting side effects develop.
Monotherapy scheme:
TNF-T (Refnot) in the dosage of 100000-400000 units at once subcutaneously 5 days a week, then a 2-day pause for a long period of time (The efficiency is proved during clinical trials conducted in the department of combined method treatment State Establishment “Russian Cancer Research Center named after Nikolai Blokhin” of the Russian Academy of Medical Sciences under the supervision of deputy director of science department, an associate member of the Russian Academy of Sciences, professor, Doctor of Medical Sciences M.R. Lichinitser).
Recommendations: The drug is injected subcutaneously to the outer surface of the upper arm or femur, the injection pointsshall be interchanged. In case of thrombocytopenia less than 80х103/µL, the injection of TNF-T (Refnot) should be stopped until the number of thrombocytes increases to the minimum of 100х103/µL. The treatment should be continued until the progress is reached or the limiting side effects develop.